ऑस्ट्रेलियाई मरीजों के लिए भारत में सर्वश्रेष्ठ ऑन्कोलॉजी डॉक्टर

No single doctor holds an official ‘number one’ title in India’s oncology field. However, Dr. Suresh H Advani (Fortis S L Raheja Hospital, Mumbai) is widely seen as the pioneer of Indian medical oncology. He was the first to do a bone marrow transplant in India. He has received the Padma Bhushan and Padma Shri, and Harvard Medical International’s Lifetime Achievement in Oncology award. For surgical oncology, Dr. KS Gopinath (Padma Shri 2010, Dr. BC Roy Award) and Dr. Shailesh Puntambekar (creator of the Pune Technique) are among the most globally recognised. At Divinheal partner hospitals, Dr. Bhawna Sirohi (Apollo Proton, FRCP, ICMR Task Force Chair) and Dr. Harit Chaturvedi (Chairman, MAX Cancer Institute) hold the highest credential tier.

Dr. Suresh H Advani is widely called the father of medical oncology in India. That title is based on real firsts. He was the first doctor to carry out a successful bone marrow transplant in India. He trained under Nobel Prize winner Dr. E Donnall Thomas. He also ran India’s first clinical trial for childhood leukaemia. He improved treatment success from 20% to 70% across 1,200 patients. He has received the Padma Bhushan (2012), the Padma Shri (2002), and Harvard’s Lifetime Achievement in Oncology award. He still works at Fortis S L Raheja Hospital, Mumbai.

The best hospital depends on what cancer you have and what treatment you need. For proton therapy and medical oncology: Apollo Proton Cancer Centre Chennai — South Asia’s first proton therapy centre, with full specialist teams. For complex surgery and blood cancers: Medanta – The Medicity, Gurgaon and Fortis Memorial Research Institute, Gurgaon. For head & neck and full cancer care: MAX Institute of Cancer Care, Delhi. For robotic urological and gynaecological oncology: Apollo Chennai and Medanta Gurgaon. Tata Memorial Hospital, Mumbai — a government centre not in the Divinheal network — is widely seen as India’s top high-volume centre for sheer case numbers and clinical trial access.

Costs vary widely by cancer type, stage, and treatment plan. Here is a reference point. A full breast cancer programme — surgery + 6 cycles chemotherapy + 5 weeks radiation — at a certified hospital in India costs ₹8,00,000–₹20,00,000 ($9,600–$24,000). The same programme privately in the UAE costs AED 200,000–600,000+ ($54,500–$163,000). In Australia, privately: AUD $60,000–$200,000+. Targeted therapy and immunotherapy add a lot to costs in every country. These are the fastest-rising cost items in cancer care worldwide.

The 5-year survival rate changes a lot by cancer type and stage. All cancers combined — 5-year survival in the USA: about 69%. By cancer type: thyroid cancer ~98%; prostate (localised) ~99%; breast cancer (all stages) ~91%; colorectal (all stages) ~65%; lung cancer (all stages) ~25%; pancreatic cancer ~12%; glioblastoma (GBM) less than 10%. New immunotherapy and targeted therapy have raised survival rates. In melanoma, the stage IV 5-year rate is now 40%+ with checkpoint inhibitors. In EGFR-mutant stage IV lung cancer, the rate is ~30% at 5 years on targeted therapy. CML patients on TKI therapy often achieve a near-normal lifespan. Source: SEER, NCI USA.

Yes — remission in stage 4 cancer is possible. It is happening more often as new treatments emerge. Stage 4 melanoma: complete response rates of 16–22% with PD-1 inhibitor monotherapy. Some patients stay in complete remission for 10 years. Stage 4 CML: most patients achieve complete cytogenetic response on imatinib or next-generation TKIs. Some reach ‘treatment-free remission’ — stopping medication while staying cancer-free. Stage 4 lung (EGFR mutation): strong responses to osimertinib (Tagrisso) in most patients. Disease control for 18–24+ months is common. Remission in stage 4 solid tumours (pancreatic, GBM, mesothelioma) is still rare. It does happen in clinical trial settings.

No. Stage 4 means the cancer has spread beyond its original site — not that death is imminent. Stage 4 melanoma, CML, some lung cancers, hormone-sensitive prostate cancer, and some lymphomas are now managed as long-term chronic conditions. Stage 4 pancreatic cancer and GBM remain the hardest to treat. Without clinical trial access, median survival is measured in months. The NCCN guidelines used at Divinheal partner hospitals guide treatment decisions for all stage 4 cancers.

Chemotherapy itself — the infusion process — is not painful. It goes through a needle in your arm using a cannula or port. The infusion takes 1–8 hours, depending on the drug. What causes discomfort is the side effects that follow. These include nausea (managed with anti-nausea medicine), fatigue, mouth sores (mucositis), and peripheral neuropathy — tingling or numbness in hands and feet with certain drugs like taxanes or oxaliplatin. Hair loss is also common. Modern supportive care at Indian certified hospitals helps a lot. This includes preventive anti-nausea drugs (ondansetron, granisetron), growth factor injections (G-CSF) to keep white cell counts stable, and mucositis prevention plans. Side effects are much less severe now than they were ten years ago.

This is a personal decision made by you and your oncologist together. Doctors may raise the question when: the cancer is growing despite treatment; side effects are badly reducing your quality of life and cannot be managed; your body is no longer strong enough to handle more treatment; or you have finished the planned course. For palliative chemotherapy — treatment to control disease rather than cure it — the goal is always to weigh benefit against burden. The aim is to extend meaningful life, not to prolong suffering. Palliative care specialists at Apollo, Medanta, and Fortis are part of the oncology team for all advanced cancer patients.

Several highly regarded robotic cancer surgeons work at Divinheal partner hospitals. For prostate, kidney, and bladder cancer: Dr. Yuvaraja T.B. is one of India’s most recognised names for robotic prostate surgery. For gynaecological cancers, Dr. Shailesh Puntambekar is known globally for the keyhole radical hysterectomy. He works at Galaxy Care Pune, which is not a current Divinheal partner. At Artemis Gurgaon and Medanta Gurgaon, dedicated robotic surgery teams perform 200+ robotic cancer procedures per year. Case volume is the most reliable sign of surgical quality.

Robotic cancer surgery at Divinheal partner hospitals costs ₹3,00,000–₹10,00,000 ($3,600–$12,000). The final cost depends on the cancer type and how complex the procedure is. This covers surgeon fees, robotic system usage fee, anaesthesia, and a standard hospital stay (3–5 days). Medicines, pre-operative tests, and post-operative follow-up are usually charged separately. At a Dubai private hospital, the same surgery costs AED 80,000–200,000+ ($21,800–$54,500). At Australian private hospitals: AUD $20,000–$60,000.

Senior consultant oncologists (10+ years experience) in Dubai private hospitals earn AED 35,000–65,000 per month ($9,500–$17,700). Specialists at Dubai Healthcare City (DHCC) and certified Dubai private hospitals are at the top of this range. This salary level directly affects what you pay for treatment in the UAE. A specialist consultation with a senior oncologist in Dubai usually costs AED 800–2,500 ($220–$680). In India, the same consultation at a certified hospital costs ₹3,000–₹8,000 ($35–$95). This cost difference flows through to all treatment pricing.

All Divinheal partner hospitals send a full discharge summary in English within 48 hours of treatment completion. Video follow-up appointments are booked at 1, 3, and 6 months after treatment ends. Your discharge summary includes the confirmed diagnosis, staging, all treatments given (drug names, doses, dates), scan and lab results, and post-treatment instructions. The format works with UAE and Australian medical record systems. For patients on ongoing oral targeted therapy or hormonal therapy, prescriptions are started in India and then continued locally under your home doctor’s care.